Mark Kawakami - 03 Feb 2025 Form 4 Insider Report for Arcadia Biosciences, Inc. (RKDA)

Reporting relationship: Chief Financial Officer
Issuer ticker: RKDA
Reported as of: 03 Feb 2025
Net transaction value: +$1,743
SEC form: 4
Accepted by SEC: 05 Feb 2025, 19:34:41 UTC
Prior SEC filing: 21 Aug 2024
Next SEC filing: 12 May 2025
Source filing: View source filing
Reporting owner signature: Mark Kawakami, by Attorney-in-fact, Solaeta Chan

Key filing fact

Mark Kawakami filed Form 4 for Arcadia Biosciences, Inc. (RKDA) on 05 Feb 2025.

Key facts

This page summarizes Mark Kawakami's Form 4 filing for Arcadia Biosciences, Inc. (RKDA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 05 Feb 2025, 19:34.

Change

Previous filing in this sequence was filed on 21 Aug 2024.
Current net transaction value: +$1,743.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RKDA transaction

Common Stock

Purchase

Transaction value: $1,743
Shares: +700
Change %: +35%
Price: $2.49
Shares after: 2,681
Date: 03 Feb 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects the purchase of 700 shares of the Issuer's common stock on 2/3/25 at a per share purchase price of $2.49 pursuant to participation in the Issuer's 2015 Employee Stock Purchase Plan ("ESPP"). This transaction is exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of Issuer's common stock.

Footnote F2

The amount includes the 2015 Employee Stock Purchase Plan ("ESPP") purchases, for the purchase periods from August 1, 2022 to February 1, 2025. These transactions were exempt from Rule 16b-3(c). In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of Issuer's Common Stock on the respective offering date or purchase date, whichever is lower.